peginesatide (Omontys) Report issue

Biologics Peptide Approved FDA First in Class
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG repoDB

Active Ingredient History

NOW
  • Now
Peginesatide, developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

af37702 | af-37702 | erythropoiesis-stimulating agent (esa) | hematide | omontys | peginesatide | peginesatide acetate

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Anemia (approved 2012)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Anemia (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Kidney Failure, Chronic (Phase 3)

Neoplasms (Phase 2)

Red-Cell Aplasia, Pure (Phase 2)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue